estrogen/testosterone combination gel

The drug contains a complex of biologically active substances, the main of which is arbutin. Arbutin is rapidly absorbed after oral administration. Splitting arbutin hydroquinone to form the free enzyme is influenced by the intestinal microflora, in particular Escherichia coli. After intestinal estrogen/testosterone combination gel absorption hydroquinone is metabolized in the liver, where they form conjugates with glucuronic and sulfuric acids. Glucuronide and sulfate hydroquinone rapidly excreted in the urine within a few hours. Most excretion occurs in the first 6 hours. 70-75% of the dose is released after 24 hours.

Indications for use
In the treatment of inflammatory diseases of the bladder and urinary tract infections (cystitis, urethritis).

Contraindications
: Hypersensitivity to the drug, acute renal and hepatic failure, acute glomerulonephritis; lactase deficiency, lactose intolerance, glucose-galactose malabsorption;Children up to age 18 years.

Precautions
When glomerulonephritis (possible irritation of the renal parenchyma).

Pregnancy and lactation
Use of the drug is contraindicated in pregnancy estrogen/testosterone combination gel and during breastfeeding.

Dosing and Administration
Inside. 1 tablet 3-4 times a day in 30 – 40 minutes after a meal.
The course of treatment – 20 – 25 days; if necessary, repeat the treatment after 10 – 12 days (not more than 4 courses per year).

Side effects:
Allergic reactions are possible; nausea, vomiting, diarrhea.
In the long-term use (more than 1 month) can be observed exacerbation of inflammation in the urinary system as a result of prolonged irritation of the renal tubules.

Overdose
So far, cases of overdose when using the drug is not registered. When taken in doses higher than recommended may increase in dose-related side effects.
Treatment: symptomatic.

Interaction with other medicinal products
are not described.

Special instructions:
Before the drug in the urine turns dark green.
Use of the drug does not affect the performance of potentially hazardous activities that require attention and fast reactions.

Form release
10 tablets in blisters.
One or two blisters with instruction on estrogen/testosterone combination gel use are placed in a stack of cardboard.
On 30 tablets in orange glass jars, sealed with caps, perforated aluminum.
At 30 tablets in banks polymer with polymeric cover or banks polymer with shock absorber and the cover tensioned to control the first opening.
Each jar along with instructions for use are placed in a stack of cardboard.